Last reviewed · How we verify
CT011 CAR-GPC3 T Cells Injection
CT011 CAR-GPC3 T Cells Injection is a Biologic drug developed by CARsgen Therapeutics Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | CT011 CAR-GPC3 T Cells Injection |
|---|---|
| Sponsor | CARsgen Therapeutics Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT011 CAR-GPC3 T Cells Injection CI brief — competitive landscape report
- CT011 CAR-GPC3 T Cells Injection updates RSS · CI watch RSS
- CARsgen Therapeutics Co., Ltd. portfolio CI
Frequently asked questions about CT011 CAR-GPC3 T Cells Injection
What is CT011 CAR-GPC3 T Cells Injection?
CT011 CAR-GPC3 T Cells Injection is a Biologic drug developed by CARsgen Therapeutics Co., Ltd..
Who makes CT011 CAR-GPC3 T Cells Injection?
CT011 CAR-GPC3 T Cells Injection is developed by CARsgen Therapeutics Co., Ltd. (see full CARsgen Therapeutics Co., Ltd. pipeline at /company/carsgen-therapeutics-co-ltd).
What development phase is CT011 CAR-GPC3 T Cells Injection in?
CT011 CAR-GPC3 T Cells Injection is in Phase 1.